MDT

88.42

-0.26%↓

VEEV

282.22

-0.26%↓

A

120.83

+0.49%↑

WBA

11.48

-0.09%↓

HQY

101.21

-1.67%↓

MDT

88.42

-0.26%↓

VEEV

282.22

-0.26%↓

A

120.83

+0.49%↑

WBA

11.48

-0.09%↓

HQY

101.21

-1.67%↓

MDT

88.42

-0.26%↓

VEEV

282.22

-0.26%↓

A

120.83

+0.49%↑

WBA

11.48

-0.09%↓

HQY

101.21

-1.67%↓

MDT

88.42

-0.26%↓

VEEV

282.22

-0.26%↓

A

120.83

+0.49%↑

WBA

11.48

-0.09%↓

HQY

101.21

-1.67%↓

MDT

88.42

-0.26%↓

VEEV

282.22

-0.26%↓

A

120.83

+0.49%↑

WBA

11.48

-0.09%↓

HQY

101.21

-1.67%↓

Search

Crinetics Pharmaceuticals Inc

Suletud

SektorTervishoid

29.43 3.66

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

28.14

Max

29.95

Põhinäitajad

By Trading Economics

Sissetulek

-16M

-97M

Müük

361K

361K

Aktsiakasum

-1.04

Kasumimarginaal

-26,807.202

Töötajad

437

EBITDA

-17M

-110M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+162.27% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

7. aug 2025

Turustatistika

By TradingEconomics

Turukapital

-467M

2.7B

Eelmine avamishind

25.77

Eelmine sulgemishind

29.43

Uudiste sentiment

By Acuity

50%

50%

163 / 380 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

Crinetics Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

2. juuli 2025, 17:03 UTC

Suurimad hinnamuutused turgudel

Furniture Companies Rise on U.S. Trade Deal With Vietnam

2. juuli 2025, 15:18 UTC

Suurimad hinnamuutused turgudel

Mogo Shares Rally After Embrace of Bitcoin Into Holdings, Operations

2. juuli 2025, 23:45 UTC

Market Talk

Global Equities Roundup: Market Talk

2. juuli 2025, 23:45 UTC

Market Talk

Nikkei May Trade Rangebound Amid U.S. Tariff Uncertainty -- Market Talk

2. juuli 2025, 23:40 UTC

Market Talk

Gold Edges Lower Amid Hopes for More Trade Deals -- Market Talk

2. juuli 2025, 21:01 UTC

Omandamised, ülevõtmised, äriostud

AT&T Completes Sale of Entire Remaining 70% Stake in DIRECTV to TPG >T

2. juuli 2025, 21:01 UTC

Omandamised, ülevõtmised, äriostud

AT&T and TPG Close DIRECTV Transaction

2. juuli 2025, 20:26 UTC

Tulu

Rivian Stock Drops on Sales Decline. The Stakes Are High for the Rest of 2025. -- Barrons.com

2. juuli 2025, 20:22 UTC

Market Talk

Gold Rises Following Weak ADP Payroll Reading -- Market Talk

2. juuli 2025, 20:13 UTC

Market Talk

Oil Price Expectations Stable in Dallas Fed Survey -- Market Talk

2. juuli 2025, 19:09 UTC

Market Talk

Oil Futures Bounce in Defiance of Downbeat Data -- Market Talk

2. juuli 2025, 19:08 UTC

Market Talk

Dollar Trims Gains as Investors Brace for Cooling Jobs Market -- Market Talk

2. juuli 2025, 19:01 UTC

Market Talk

U.S. Natural Gas Ticks Up Ahead of Storage Data -- Market Talk

2. juuli 2025, 18:08 UTC

Market Talk

Fossil Fuels Rule Energy Roost As U.S. Marks Independence -- Market Talk

2. juuli 2025, 17:06 UTC

Omandamised, ülevõtmised, äriostud

BCE: Maple Leafs, Raptors Rights Access Through Long-Term Agreement With Rogers, Subject to League Approvals

2. juuli 2025, 17:05 UTC

Omandamised, ülevõtmised, äriostud

BCE: Access to Content Rights for Toronto Maple Leafs, Toronto Raptors on TSN Secured Through 2043/2044 Season

2. juuli 2025, 17:04 UTC

Omandamised, ülevõtmised, äriostud

BCE: Proceeds of MLSE Stake Sale to Support Financing of Acquisition of Ziply Fiber

2. juuli 2025, 17:04 UTC

Omandamised, ülevõtmised, äriostud

BCE Inc. Concludes Sale of Minority Stake in Maple Leaf Sports & Entertainment

2. juuli 2025, 17:02 UTC

Omandamised, ülevõtmised, äriostud

Rogers Communications: Now Largest Owner With 75% Interest in Maple Leaf Sports & Entertainment

2. juuli 2025, 17:02 UTC

Omandamised, ülevõtmised, äriostud

Rogers Communications Closes Deal to Buy BCE's 37.5% Stake in Maple Leaf Sports & Entertainment for C$4.7B

2. juuli 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

2. juuli 2025, 16:20 UTC

Market Talk

Cushing Crude Stock Slide Keeps Bid in WTI -- Market Talk

2. juuli 2025, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

2. juuli 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

2. juuli 2025, 16:11 UTC

Market Talk

Copper Prices Hold Higher on Supply Disruption, Tariff Uncertainty -- Market Talk

2. juuli 2025, 16:09 UTC

Market Talk

Gold Futures Rise, Recouping Some Losses -- Market Talk

2. juuli 2025, 15:59 UTC

Tulu

These Stocks Are Moving the Most Today: Tesla, Centene, Apple, Adobe, Rigetti Computing, Greenbrier, and More -- Barrons.com

2. juuli 2025, 15:17 UTC

Market Talk

Oil Market to Keep Close Watch on U.S. Payrolls -- Market Talk

2. juuli 2025, 15:08 UTC

Market Talk

Luxury Sector Should Report a Slowdown -- Market Talk

2. juuli 2025, 15:00 UTC

Omandamised, ülevõtmised, äriostud

Glencore: Merger of Viterra With Bunge Global Closed

Võrdlus sarnastega

Hinnamuutus

Crinetics Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

162.27% tõus

12 kuu keskmine prognoos

Keskmine 75.43 USD  162.27%

Kõrge 97 USD

Madal 60 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Crinetics Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

8 ratings

8

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

30.39 / 33.46Toetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Neutral Evidence

Sentiment

By Acuity

163 / 380 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.